Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IP…
FAIL · Does not pass the screen
12.61 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 7 days ago
Screened 2026-10-23 · the tape above runs as of 14:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price12.61 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.04)
Last reviewed23 Oct 2026 (7 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 12.61 against the desk's fair-value range, base estimate 25.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.04, read 2026-10-28
Ethical does not pass the values gate
Price12.61 USD
Fair value25.00
Ethical score70.0/100
Our investment reviews on this name
2026-09-15Read Markdown17.96-29.8% to today ✓Markup gives way to Markdown
2026-08-15Read Markup17.73-28.9% to today Accumulation gives way to Markup after a 25% rise in 6 weeks
2026-07-02Read Accumulation14.21-11.3% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Trevi Therapeutics, Inc. holds its Markdown at $12.61. The statistical read favours the sellers, held for 48 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 48 days
Price at the screen
$12.61
Valuation
N/A trailing · -22.13 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.98
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.39%
Below 33%
Interest-bearing debt is just 0.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
87.54%
Below 33%
Interest-bearing cash and securities are 87.5% of assets, above the one-third limit.
Fail
Receivables
9.78%
Below 49%
Money owed to the company is 9.8% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Trevi Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 88% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when TRVI's ethical verdict changes
Today TRVI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 98.3% margin of safety to the base estimate.
Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +98% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Chronic Cough Biotech Hits Ethical Data Wall
Picture a firm pouring cash into trials for a cough drug aimed at scarred lungs, yet still years from any revenue. Trevi sits at that exact stage, a clinical biotech with zero profit margin and a return on equity stuck at minus 34 percent. Analysts see promise and set a 24 dollar target, but the numbers simply are not there yet.
We pass. The ethical screen returns insufficient data because basic financial ratios are missing, and a forward price to earnings ratio of minus 34 times tells us nothing useful when earnings do not exist. Without those foundations we cannot weigh the business against our standards, regardless of the strong buy consensus.
Risk sits in the usual clinical stage traps: trial failures, repeated cash raises and dilution. The 26 percent margin to the 24 dollar fair value looks attractive on paper, yet it rests on hope rather than proven cash flow. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TRVI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markdown$12.77+5.9%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 8% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (10 analysts) rates it strong buy, with a mean price target of $24.
2026-10-21Markdown$12.06-8.6%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it D. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (10 analysts) rates it strong buy, with a mean price target of $24.
2026-10-14Markdown$13.19-11.8%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (10 analysts) rates it strong buy, with a mean price target of $24.
2026-10-02Markdown$14.95-16.8%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 16.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (10 analysts) rates it strong buy, with a mean price target of $24.
2026-09-15Markdown · changed$17.96+1.3%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (10 analysts) rates it strong buy, with a mean price target of $24.
2026-08-15Markup · changed$17.73+24.8%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 24.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (10 analysts) rates it strong buy, with a mean price target of $24.
2026-07-18Accumulation$14.21+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 28% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 106%. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (10 analysts) rates it strong buy, with a mean price target of $24.
2026-07-03Accumulation$14.21+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$14.21Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
